Response to the Comment on "Prognosis-based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines"

Richard D Schulick^{1

2

3}, Atsushi Oba^{4

5

6}, Marco Del Chiaro^{1

2

3}

Affiliations

¹ Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus.
² Aurora, Colorado.
³ University of Colorado Cancer Center, Denver, Colorado.
⁴ Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
⁵ Department of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research.
⁶ Tokyo, Japan.

Comment

Richard D Schulick et al. Ann Surg. 2021.

. 2021 Dec 1;274(6):e770-e771.

doi: 10.1097/SLA.0000000000004275.

Richard D Schulick^{1

2

3}, Atsushi Oba^{4

5

6}, Marco Del Chiaro^{1

2

3}

¹ Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus.
² Aurora, Colorado.
³ University of Colorado Cancer Center, Denver, Colorado.
⁴ Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
⁵ Department of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research.
⁶ Tokyo, Japan.

No abstract available

Conflict of interest statement

The authors declare no conflicts of interest.

Prognosis Based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines.
Oba A, Croce C, Hosokawa P, Meguid C, Torphy RJ, Al-Musawi MH, Ahrendt S, Gleisner A, Schulick RD, Del Chiaro M. Oba A, et al. Ann Surg. 2022 Jan 1;275(1):175-181. doi: 10.1097/SLA.0000000000003859. Ann Surg. 2022. PMID: 32149822
Comment on "Prognosis-based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines".
Wei MY, Hua J, Yu XJ, Shi S. Wei MY, et al. Ann Surg. 2021 Dec 1;274(6):e769-e770. doi: 10.1097/SLA.0000000000004291. Ann Surg. 2021. PMID: 32740258 No abstract available.

1. Oba A, Croce C, Hosokawa P, et al. Prognosis based definition of resectability in pancreatic cancer: a road map to new guidelines. Ann Surg 2020; [published online ahead of print, 2020 Mar 6]. DOI: 10.1097/SLA.0000000000003859. - DOI
1. Wagner M, Antunes C, Pietrasz D, et al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol 2017; 27:3104–3116.
1. Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg 2019; 270:340–347.
1. Oba A, Bao QR, Barnett CC, et al. Vascular resections for pancreatic ductal adenocarcinoma: vascular resections for PDAC. Scand J Surg 2020; 109:18–28.
1. Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015; 261:12–17.